Advertisement

Representativity of TMA Studies

  • Guido SauterEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 664)

Abstract

The smaller the portion of a tumor sample that is analyzed becomes, the higher is the risk of missing important histological or molecular features that might be present only in a subset of tumor cells. Many researchers have, therefore, suggested using larger tissue cores or multiple cores from the same donor tissue to enhance the representativity of TMA studies. However, numerous studies comparing the results of TMA studies with the findings from conventional large sections have shown that all well-established associations between molecular markers and tumor phenotype or patient prognosis can be reproduced with TMAs even if only one single 0.6 mm tissue spot is analyzed. Moreover, the TMA technology has proven to be superior to large section analysis in finding new clinically relevant associations. The high number of samples that are typically included in TMA studies, and the unprecedented degree of standardization during TMA experiments and analysis often give TMA studies an edge over traditional large-section studies.

Key words

Tissue microarray TMA representativity TMA core diameter Tissue heterogeneity Translational research 

References

  1. 1.
    Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., Kallioniemi, O. P. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med; 7:844–7.CrossRefGoogle Scholar
  2. 2.
    Khalique, L., Ayhan, A., Weale, M. E., Jacobs, I. J., Ramus, S. J., Gayther, S. A. (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol; 3:286–95.CrossRefGoogle Scholar
  3. 3.
    Simon, R., Burger, H., Brinkschmidt, C., Bocker, W., Hertle, L., Terpe, H. J. (1998) Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol; 4:345–51.CrossRefGoogle Scholar
  4. 4.
    Sauter, G., Mihatsch, M. J. (1998) Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol; 4:339–41.CrossRefGoogle Scholar
  5. 5.
    Robanus-Maandag, E. C., Bosch, C. A., Kristel, P. M., Hart, A. A., Faneyte, I. F., Nederlof, P. M., Peterse, J. L., van de Vijver, M. J. (2003) Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol; 1:75–82.CrossRefGoogle Scholar
  6. 6.
    Cho, E. Y., Han, J. J., Choi, Y. L., Kim, K. M., Oh, Y. L. (2008) Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci; 6:1053–61.CrossRefGoogle Scholar
  7. 7.
    Simon, R., Eltze, E., Schafer, K. L., Burger, H., Semjonow, A., Hertle, L., Dockhorn-Dworniczak, B., Terpe, H. J., Bocker, W. (2001) Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res; 1:355–62.Google Scholar
  8. 8.
    Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Kochli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., Kallioniemi, O. P., Sauter, G. (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol; 6:2249–56.CrossRefGoogle Scholar
  9. 9.
    Camp, R. L., Charette, L. A., Rimm, D. L. (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest; 12:1943–9.CrossRefGoogle Scholar
  10. 10.
    Hendriks, Y., Franken, P., Dierssen, J. W., De Leeuw, W., Wijnen, J., Dreef, E., Tops, C., Breuning, M., Brocker-Vriends, A., Vasen, H., Fodde, R., Morreau, H. (2003) Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol; 2:469–77.CrossRefGoogle Scholar
  11. 11.
    Ruiz, C., Seibt, S., Al Kuraya, K., Siraj, A. K., Mirlacher, M., Schraml, P., Maurer, R., Spichtin, H., Torhorst, J., Popovska, S., Simon, R., Sauter, G. (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer; 9:2190–4.CrossRefGoogle Scholar
  12. 12.
    Hoos, A., Urist, M. J., Stojadinovic, A., Mastorides, S., Dudas, M. E., Leung, D. H., Kuo, D., Brennan, M. F., Lewis, J. J., Cordon-Cardo, C. (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol; 4:1245–51.CrossRefGoogle Scholar
  13. 13.
    Nocito, A., Bubendorf, L., Tinner, E. M., Suess, K., Wagner, U., Forster, T., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knonagel, H., Rist, M., Anabitarte, M., Hering, F., Hardmeier, T., Schoenenberger, A. J., Flury, R., Jager, P., Fehr, J. L., Schraml, P., Moch, H., Mihatsch, M. J., Gasser, T., Sauter, G. (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol; 3:349–57.CrossRefGoogle Scholar
  14. 14.
    Moch, H., Schraml, P., Bubendorf, L., Mirlacher, M., Kononen, J., Gasser, T., Mihatsch, M. J., Kallioniemi, O. P., Sauter, G. (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol; 4:981–6.CrossRefGoogle Scholar
  15. 15.
    Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., Kallioniemi, O. P., Kallioniemi, A. (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst; 15:1252–9.CrossRefGoogle Scholar
  16. 16.
    Garcia, J. F., Camacho, F. I., Morente, M., Fraga, M., Montalban, C., Alavaro, T., Bellas, C., Castano, A., Diez, A., Flores, T., Martin, C., Martinez, M. A., Mazorra, F., Menarguez, J., Mestre, M. J., Mollejo, M., Saez, A. I., Sanchez, L., Piris, M. A. (2002) Hodgkin’s and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue-microarrays. Blood; 101:681–89.PubMedCrossRefGoogle Scholar
  17. 17.
    Hedvat, C. V., Hegde, A., Chaganti, R. S., Chen, B., Qin, J., Filippa, D. A., Nimer, S. D., Teruya-Feldstein, J. (2002) Application of tissue microarray technology to the study of non-Hodgkin’s and Hodgkin’s lymphoma. Hum Pathol; 10:968–74.CrossRefGoogle Scholar
  18. 18.
    Tzankov, A., Zimpfer, A., Lugli, A., Krugmann, J., Went, P., Schraml, P., Maurer, R., Ascani, S., Pileri, S., Geley, S., Dirnhofer, S. (2003) High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin’s lymphoma indicates overexpression of cyclin E1. J Pathol; 2:201–7.CrossRefGoogle Scholar
  19. 19.
    Hoos, A., Stojadinovic, A., Mastorides, S., Urist, M. J., Polsky, D., Di Como, C. J., Brennan, M. F., Cordon-Cardo, C. (2001) High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer; 4:869–74.CrossRefGoogle Scholar
  20. 20.
    Hoos, A., Stojadinovic, A., Singh, B., Dudas, M. E., Leung, D. H., Shaha, A. R., Shah, J. P., Brennan, M. F., Cordon-Cardo, C., Ghossein, R. (2002) Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol; 1:175–83.CrossRefGoogle Scholar
  21. 21.
    Rubin, M. A., Dunn, R., Strawderman, M., Pienta, K. J. (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol; 3:312–9.CrossRefGoogle Scholar
  22. 22.
    Engellau, J., Akerman, M., Anderson, H., Domanski, H. A., Rambech, E., Alvegard, T. A., Nilbert, M. (2001) Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol; 4:358–63.CrossRefGoogle Scholar
  23. 23.
    Fernebro, E., Dictor, M., Bendahl, P. O., Ferno, M., Nilbert, M. (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med; 6:702–5.Google Scholar
  24. 24.
    Zhang, D., Salto-Tellez, M., Putti, T. C., Do, E., Koay, E. S. (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol; 1:79–84.CrossRefGoogle Scholar
  25. 25.
    Kristiansen, G., Fritzsche, F. R., Wassermann, K., Jager, C., Tolls, A., Lein, M., Stephan, C., Jung, K., Pilarsky, C., Dietel, M., Moch, H. (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer; 6:939–48.CrossRefGoogle Scholar
  26. 26.
    Schlomm, T., Kirstein, P., Lwers, L., Daniel, B., Steuber, T., Walz, J., Chun, F. H. K., Haese, A., Kollermann, J., Graefen, M., Huland, H., Sauter, G., Simon, R., Erbersdobler, A. (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res; 22:6579–84.CrossRefGoogle Scholar
  27. 27.
    Erbersdobler, A., Isbarn, H., Steiner, I., Schlomm, T., Chun, F., Mirlacher, M., Sauter, G. (2009) Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology; 74:1169–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Kollermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., Haese, A., Steuber, T., Simon, R., Huland, H., Sauter, G., Erbersdobler, A. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol; 21:1371–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Fleischmann, A., Schlomm, T., Huland, H., Kollermann, J., Simon, P., Mirlacher, M., Salomon, G., Chun, F. H., Steuber, T., Simon, R., Sauter, G., Graefen, M., Erbersdobler, A. (2008) Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res; 23:7838–42.CrossRefGoogle Scholar
  30. 30.
    Fleischmann, A., Schlomm, T., Kollermann, J., Sekulic, N., Huland, H., Mirlacher, M., Sauter, G., Simon, R., Erbersdobler, A. (2009) Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate; 69:976–81.PubMedCrossRefGoogle Scholar
  31. 31.
    Zellweger, T., Ninck, C., Bloch, M., Mirlacher, M., Koivisto, P. A., Helin, H. J., Mihatsch, M. J., Gasser, T. C., Bubendorf, L. (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer; 4:619–28.CrossRefGoogle Scholar
  32. 32.
    Vergis, R., Corbishley, C. M., Norman, A. R., Bartlett, J., Jhavar, S., Borre, M., Heeboll, S., Horwich, A., Huddart, R., Khoo, V., Eeles, R., Cooper, C., Sydes, M., Dearnaley, D., Parker, C. (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol; 4:342–51.CrossRefGoogle Scholar
  33. 33.
    Lin, B., Utleg, A. G., Gravdal, K., White, J. T., Halvorsen, O. J., Lu, W., True, L. D., Vessella, R., Lange, P. H., Nelson, P. S., Hood, L., Kalland, K. H., Akslen, L. A. (2008) WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res; 5:1397–406.CrossRefGoogle Scholar
  34. 34.
    Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., Schotzau, A., Kononen, J., Sauter, G. (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst; 15:1141–6.CrossRefGoogle Scholar
  35. 35.
    Fleiner, M., Kummer, M., Mirlacher, M., Sauter, G., Cathomas, G., Krapf, R., Biedermann, B. C. (2004) Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation; 18:2843–50.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Institute of PathologyUniversity Medical Center Hamburg EppendorfHamburgGermany

Personalised recommendations